115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Voss, M. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic profiling of bladder cancer in waterpipe and cigarette smokers: Implications for carcinogenicity and genetic landscape
    Meeting Abstract

    Shamseddine, A.; Abbas, N.; Chatila, W. K.; Walch, H. S.; Eichholz, J.; Schultz, N.; Solit, D. B.; Charafeddine, M.; Al Darazi, M.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Saad, E.; Labaki, C.; Miron, B.; Park, J.; Bakouny, Z.; Nassar, A.; Saliby, R. M.; Semaan, K.; Eid, M.; Meli, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma
    Meeting Abstract

    Dayyani, F.; Baretti, M.; Lee, S. S.; He, A. R.; Kim, R. D.; Lin, B. S. L.; Enzler, T.; Al Hallak, M. N.; Ulahannan, S. V.; Davis, S. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)
    Meeting Abstract

    Janjigian, Y. Y.; Raoufmoghaddam, S.; Sztachelska, M.; Winter, M.; Das, S.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
    Meeting Abstract

    Deming, D. A.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.; Iyer, G.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Heinrich, M. C.; Somaiah, N.; Trent, J. C.; Wilky, B. A.; Burgess, M. A.; Singh, A. S.; Attia, S.; Agulnik, M.; Tap, W. D.; Bauer, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update
    Meeting Abstract

    Segal, N. H.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Han, H.; Casey, K. A.; Li, S.; Ganguly, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma
    Meeting Abstract

    Wainberg, Z. A.; Chung, V.; Devoe, C. E.; George, T. J.; Welkowsky, E.; Kheoh, T.; Haqq, C. M.; Pant, S.; O'Reilly, E. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - Evaluating radiation, ablation, and surgery (ERASur)
    Meeting Abstract

    Hitchcock, K.; Romesser, P. B.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S. B.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save